Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prevention in Lung Transplant Recipients With IPF
NCT05041426Phase 2Completed
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms). Primary endpoints: Occurrence of CMV Infection or Disease During Prophylaxis at 12 months and Occurrence of CMV Infection or Disease in the 3 Months Following Completion of Prophylaxis. Started Dec 2021; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05041426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041426.